Natera announces surveillance analysis from IMvigor011 study

Natera announced an analysis from the IMvigor011 study that was presented at the European Association of Urology Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer patients who tested serially negative with Signater, Natera’s personalized and tumor-informed molecular residual disease test. The analysis presented at the EAU Congress evaluated clinical outcomes in 171 high-risk MIBC patients who entered screening for IMvigor011 and remained MRD-negative during the surveillance window. Key takeaways from the presentation include: Overall survival rates of 100% at 12 months and 98% at 18 months, in patients who remained serially MRD-negative. Disease-free survival rates of 92% at 12 months and 88% at 18 months, in patients who remained serially MRD-negative. Concludes that patients who remain MRD-negative on serial testing may be spared from adjuvant treatment.